Conversion therapy for unresectable hepatocellular carcinoma: Advances and challenges

doi:10.4251/wjgo.v16.i10.4289

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (784)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

HTML

537

Tables (1-1)

154

Sum=711

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=56

Oct 15, 2024 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4289-4297
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4289

Conversion therapy for unresectable hepatocellular carcinoma: Advances and challenges

Yan-Fei He

Yan-Fei He, Department of Health Management Center, The Sixth Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100048, China

Author contributions: He YF designed the study, collected the data, reviewed the literature, drafted and revised the manuscript, and have read and approved the final manuscript.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Yan-Fei He, MD, Associate Chief Physician, Doctor, Department of Health Management Center, The Sixth Medical Center, Chinese People’s Liberation Army General Hospital, No. 6 Fucheng Road, Haidian District, Beijing 100048, China. heyanfeilc@163.com

Received: March 2, 2024
Revised: August 29, 2024
Accepted: September 5, 2024
Published online: October 15, 2024
Processing time: 208 Days and 6.4 Hours

Core Tip

Core Tip: This letter reviews recent advances in conversion therapy for hepatocellular carcinoma (HCC), comparatively describes the characteristics of different conversion programs, addresses current challenges in conversion therapy, highlights the complexity of conversion therapy for moderately advanced HCC, and emphasizes the importance of a multidisciplinary, team-based management model, and provides valuable insights into the treatment of unresectable HCC.